NATRNature's Sunshine Products, Inc.
Nature's Sunshine Products, Inc. sells herbal and nutritional supplements, leveraging a direct-to-consumer model with a focus on digital growth. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain revenue growth and margin expansion amid ongoing trade policy uncertainty.
- Revenue grew 5.7% YoY to $482.97M in 2026, with a net margin of 4.0% (TTM).
- Free cash flow (TTM) reached $15.18M, reflecting disciplined capital allocation.
- Debt-to-equity ratio of 0.01x highlights a low-leverage balance sheet.
The Read
4% around June 15 macro events, reflecting investor focus on strong digital growth and record results despite tariff concerns, with similar median 4.
The schedule
- Thu5Nov
The earnings release will test whether the company can maintain its guidance and deliver on its margin and cash flow targets, which are critical for sustaining its current valuation. This differs from the last print where the guidance cut led to a bearish outcome.
- Fri15Jan
The leadership transition will test whether the new CEO can deliver on the company's strategic goals and maintain investor confidence during a period of change. This differs from the last print where the focus was on short-term cash flow.
- Sun14Feb
This release will test the company's ability to deliver on its full-year guidance and show progress in its cost optimization initiatives. The last print saw a bearish outcome due to a miss on revenue and margin expectations.
- Thu6May
The release will test the company's ability to sustain its momentum and deliver on its long-term growth strategy, particularly in its international markets. This differs from the last print where the focus was on short-term cash flow.
- Thu5Aug
This release will test the company's ability to execute its strategic initiatives and deliver on its long-term growth targets, particularly in its product innovation and market expansion. This differs from the last print where the focus was on short-term cash flow.
Past
- Thu6Aug
Actual outcome: Bear · $14.65 at outcome
Nature's Sunshine Products reported Q2 2026 earnings in line with expectations, with net sales reaching $117 million, its strongest quarter in history. However, the stock fell sharply, breaking below the bear floor, likely due to concerns over long-term growth prospects and cash burn, despite positive earnings and leadership changes.
Q2 2026 Earnings & Capital Allocation Announcement evaluating top-line momentum and cash burn trajectory.
- Wed1Jul
Actual outcome: Mixed · $21.58 at outcome
Although the stock experienced a muted 1.7% decline by the initial outcome date, shares subsequently plummeted to $15.12, breaching the $19.50 bear floor. This severe delayed sell-off was driven by escalating international regulatory scrutiny and compliance contagion risks within the direct-selling sector, which ultimately undermined investor confidence in the company's operational outlook.
Assessment of potential regulatory scrutiny and direct-selling compliance contagion risk across international markets.
- Mon15Jun
Actual outcome: Bull · $20.67 at outcome
Nature's Sunshine shares rallied as the market focused on the company's successful digital transformation rather than potential herbal import tariffs. Investor confidence was driven by record FY2025 results and strong Q1 2026 momentum, highlighted by a 98% year-over-year increase in digital customers that is fueling robust North American growth.
Evaluation of President Trump's administration tariff impacts on imported raw herbal ingredients and botanical supply chains.
- Thu7May
Actual outcome: Bear · $22.43 at outcome
Nature's Sunshine delivered a mixed fundamental outcome; while the company achieved strong top-line and margin growth with net sales up 9% to $122.9 million and adjusted EBITDA jumping 33%, adjusted EPS of $0.23 merely met analyst estimates. Without a definitive bottom-line beat to validate the stock's recent run near 52-week highs, the results failed to catalyze a push toward the $26.50 bull target, leaving shares to drift lower to $24.55 by the run date.
Q1 2026 results will be the first checkpoint against Nature's Sunshine's strong 2026 revenue guidance, with the stock at $24.84 already near its 52-week high; a clean beat on growth and margins could push shares toward $26.50, while any early cracks in the guidance trajectory or FX/margin pressure could send the stock back toward $26.50.
- Tue10Mar
Actual outcome: Mixed · $24.49 at outcome
Nature's Sunshine reported Q4 2025 earnings that met EPS estimates of $0.23, alongside strong full-year revenue of $480.1 million and upbeat 2026 guidance targeting $500–$515 million in revenue. Despite the positive fundamental results and reports of an initial post-market surge, the stock's actual price reaction was muted, falling 2.4% by the outcome date and eventually drifting toward the bear floor in the following months. The outcome is classified as mixed because the strong operational performance and robust DTC growth failed to generate sustained upward price momentum, resulting in a relatively flat initial move.
Release of year-end 2025 results and critical 2026 forward guidance.
